These findings confirm that the knockout of BIN1 increases both the stability of G3BP1 and its binding affinity for STAT1, thereby suppressing the expression of CXCL10 and CCL5 via decreased STAT1 levels, highlighting potential therapeutic applications for NSCLC patients. Here, G3BP1 is linked to non-small cell lung carcinoma.